Drug intelligence / Profile preview

MABS-03

Development stage: Preclinical
Lead developer: Manhattan Biosolutions
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MABS-03 is a preclinical-stage antibody-drug conjugate (ADC) being developed by Manhattan BioSolutions for the treatment of solid tumors. The asset is constructed using the company's proprietary TxD (Targeted X-linked Delivery) platform, which is designed to optimize the linker-payload interface to enhance the therapeutic window and stability of the conjugate. While the specific tumor-associated antigen targeted by MABS-03 and the identity of its cytotoxic payload have not been publicly disclosed, the program represents a key component of the developer's oncology pipeline aimed at addressing various solid malignancies.

Beyond the preview

Go deeper on MABS-03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MABS-03.

Explore the full profile